SAGE Sage TherapeuticsWatchlist
About Sage Therapeutics Company
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.
Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited
New York, USA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Postpartum Depression Market to Exhibit Positive Growth During the Forecast Period (2023–2032), Predicts DelveInsight | Key Companies in the Market - Sage
Hold Rating on SAGE Therapeutics: Disappointing Zurzuvae Pricing and Uncertain Regulatory Path
SAGE Therapeutics (SAGE) Receives a Hold From Truist Financial
$Salesforce(CRM.US)$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US)$ popp...
follow for daily watchlist 🚀